NAS:CPRX (USA) Also trade in: Germany

Catalyst Pharmaceuticals Inc

$ 3.61 0.03 (0.84%)
Volume: 842,288 Avg Vol (1m): 3,026,260
Market Cap $: 371.29 Mil Enterprise Value $: 325.66 Mil
P/E (TTM): 0.00 P/B: 7.25
Earnings Power Value 0.3
Net Current Asset Value 0.44
Tangible Book 0.5
Projected FCF -1.21
Median P/S Value 8.97
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
97.32% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
CPRX: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset 0.84
Equity-to-Asset ranked lower than
100.00% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
CPRX: 0.84
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.84, Med: 0.84, Max: 0.95
Current: 0.84
0.84
0.95
Interest Coverage No Debt
Interest Coverage ranked higher than
97.38% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
CPRX: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 18.17
DISTRESS
GREY
SAFE
Beneish M-Score 35.69
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -2442.07%
WACC 19.71%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -234.40
Operating Margin ranked lower than
100.00% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
CPRX: -234.4
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -7059, Med: -3940.95, Max: -234.4
Current: -234.4
-7059
-234.4
Net Margin % -223.58
Net Margin ranked lower than
100.00% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
CPRX: -223.58
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -6800.8, Med: -3810.01, Max: -223.58
Current: -223.58
-6800.8
-223.58
ROE % -46.19
ROE ranked lower than
80.41% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
CPRX: -46.19
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -137.75, Med: -53.2, Max: -30.62
Current: -46.19
-137.75
-30.62
ROA % -42.24
ROA ranked lower than
83.24% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
CPRX: -42.24
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -105.81, Med: -45.7, Max: -28.97
Current: -42.24
-105.81
-28.97
ROC (Joel Greenblatt) % -13093.18
ROC (Joel Greenblatt) ranked lower than
97.31% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
CPRX: -13093.18
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -26055.36, Med: -15666.5, Max: -7059.65
Current: -13093.18
-26055.36
-7059.65
3-Year Total EBITDA Growth Rate -20.10
3-Year EBITDA Growth Rate ranked lower than
62.93% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
CPRX: -10.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -51.2, Med: -1.7, Max: 30.7
Current: -10.9
-51.2
30.7
3-Year EPS w/o NRI Growth Rate -9.70
3-Year EPS w/o NRI Growth Rate ranked lower than
55.66% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
CPRX: -9.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -48.5, Med: -7.1, Max: 33.7
Current: -9.7
-48.5
33.7

» CPRX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CPRX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare SZSE:002864 NYSE:DPLO XKRX:249420 TPE:3705 HKSE:02633 XKRX:243070 XKRX:065660 XCNQ:ACRG.U TSX:FIRE XCNQ:FONE TSXV:XLY NAS:COLL SZSE:000790 BSP:OFSA3 ASX:NXS TSE:4577 XKRX:234080 SHSE:603168 NAS:OPTN SZSE:300519
Traded in other countries CN2.Germany
Address 355 Alhambra Circle, Suite 1250, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.

Ratios

Current vs industry vs history
Forward PE Ratio 39.84
Forward P/E ranked lower than
100.00% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
CPRX: 39.84
Ranked among companies with meaningful Forward P/E only.
N/A
PB Ratio 7.25
PB Ratio ranked lower than
69.35% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
CPRX: 7.25
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.35, Med: 9.33, Max: 29.61
Current: 7.25
2.35
29.61
PS Ratio 28.66
PS Ratio ranked lower than
100.00% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
CPRX: 28.66
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 16.8, Med: 71.2, Max: 582
Current: 28.66
16.8
582
EV-to-EBIT -10.74
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
CPRX: -10.74
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -23.6, Med: -7.9, Max: -1.5
Current: -10.74
-23.6
-1.5
EV-to-EBITDA -10.75
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
CPRX: -10.75
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -23.8, Med: -8, Max: -1.5
Current: -10.75
-23.8
-1.5
EV-to-Revenue 25.15
EV-to-Revenue ranked lower than
100.00% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
CPRX: 25.15
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 14.2, Med: 73.5, Max: 491
Current: 25.15
14.2
491
Current Ratio 6.08
Current Ratio ranked higher than
96.84% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
CPRX: 6.08
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.75, Med: 15.35, Max: 54.56
Current: 6.08
0.75
54.56
Quick Ratio 6.07
Quick Ratio ranked higher than
96.84% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
CPRX: 6.07
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.75, Med: 15.35, Max: 54.56
Current: 6.07
0.75
54.56
Days Inventory 6.52
Days Inventory ranked lower than
100.00% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
CPRX: 6.52
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 0, Med: 0, Max: 6.52
Current: 6.52
0
6.52
Days Sales Outstanding 204.40
Days Sales Outstanding ranked lower than
100.00% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
CPRX: 204.4
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0, Med: 0, Max: 204.4
Current: 204.4
0
204.4
Days Payable 626.81
Days Payable ranked lower than
100.00% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
CPRX: 626.81
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 0, Med: 0, Max: 626.81
Current: 626.81
0
626.81

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -7.40
3-Year Share Buyback Rate ranked lower than
71.10% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
CPRX: -7.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -74.4, Med: -26, Max: -7.4
Current: -7.4
-74.4
-7.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 7.22
Price-to-Tangible-Book ranked lower than
59.28% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
CPRX: 7.22
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.25, Med: 3.64, Max: 10.24
Current: 7.22
1.25
10.24
Price-to-Median-PS-Value 0.40
Price-to-Median-PS-Value ranked lower than
100.00% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
CPRX: 0.4
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.39, Med: 0.73, Max: 5.33
Current: 0.4
0.39
5.33
Earnings Yield (Joel Greenblatt) % -9.31
Earnings Yield (Greenblatt) ranked lower than
82.70% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
CPRX: -9.31
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -68.8, Med: -12.7, Max: -4.2
Current: -9.31
-68.8
-4.2

More Statistics

Revenue (TTM) (Mil) $ 12.95
EPS (TTM) $ -0.29
Beta 2.95
Volatility % 107.18
52-Week Range $ 1.85 - 6.16
Shares Outstanding (Mil) 102.85

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y